| General Information of Drug Metabolite (DM) (ID: DM003518) |
| DM Name |
MP-513 Metabolite M1
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2D6 (CYP2D6)
|
DME0009
|
| Oxidation - Thiazolidine-1-oxidation |
MP-513
|
[1] , [2] |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Oxidation - Thiazolidine-1-oxidation |
MP-513
|
[1] , [2] |
|
Dimethylaniline oxidase 1 (FMO1)
|
DME0059
|
| Oxidation - Thiazolidine-1-oxidation |
MP-513
|
[1] , [2] |
|
Dimethylaniline oxidase 3 (FMO3)
|
DME0039
|
| Oxidation - Thiazolidine-1-oxidation |
MP-513
|
[1] , [2] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| MP-513 |
DR1809
|
Phase 1 |
Diabetes mellitus |
|
|
| References |
| 1 |
Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans
|
| 2 |
Development of a liquid chromatography/tandem-mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
